Bone metastasis of malignant tumor of prostate suggests that the stage of the disease is late, and the specific survival time is related to the severity of the disease and the physical quality of the patient. After prostate malignant tumor bone metastasis, radiotherapy and targeted therapy can be chosen to inhibit the malignant proliferation of tumor cells, reduce the tumor foci, improve the patient’s quality of life and prolong the patient’s survival time. Chemotherapy drugs include paclitaxel, fluorouracil, cisplatin and so on; targeted drugs include cabozantinib, bevacizumab and so on. As the drug is not absolutely effective and safe, need to follow the doctor’s instructions to standardize the use of drugs, the emergence of adverse reactions to drugs in a timely manner to seek medical treatment, drug allergy is prohibited. Therefore, it is recommended that patients relax their minds and actively cooperate with doctors to receive standardized treatment, which can help prolong the survival time and improve the prognosis of the disease.